CR20150094A - Variantes de los polipeptidos del receptor de activina y usos de los mismos - Google Patents
Variantes de los polipeptidos del receptor de activina y usos de los mismosInfo
- Publication number
- CR20150094A CR20150094A CR20150094A CR20150094A CR20150094A CR 20150094 A CR20150094 A CR 20150094A CR 20150094 A CR20150094 A CR 20150094A CR 20150094 A CR20150094 A CR 20150094A CR 20150094 A CR20150094 A CR 20150094A
- Authority
- CR
- Costa Rica
- Prior art keywords
- activine
- variations
- same
- receptor polypeptides
- activin
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108010059616 Activins Proteins 0.000 abstract 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 abstract 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 abstract 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 1
- 102100026818 Inhibin beta E chain Human genes 0.000 abstract 1
- 108010056852 Myostatin Proteins 0.000 abstract 1
- 239000000488 activin Substances 0.000 abstract 1
- 108010023082 activin A Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
Abstract
La presente invención provee polipéptidos y proteínas variantes del receptor de activina IIB solubles, los cuales son capaces de unirse e inhibir las actividades de la activina A, miostatina o GDF-11.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90545907P | 2007-03-06 | 2007-03-06 | |
US6547408P | 2008-02-11 | 2008-02-11 | |
PCT/US2008/003119 WO2008109167A2 (en) | 2007-03-06 | 2008-03-06 | Variant activin receptor polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150094A true CR20150094A (es) | 2015-04-14 |
Family
ID=39739001
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11054A CR11054A (es) | 2007-03-06 | 2009-10-05 | Variantes de los polipeptidos del receptor de activina y usos de los mismos |
CR20150094A CR20150094A (es) | 2007-03-06 | 2015-02-24 | Variantes de los polipeptidos del receptor de activina y usos de los mismos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11054A CR11054A (es) | 2007-03-06 | 2009-10-05 | Variantes de los polipeptidos del receptor de activina y usos de los mismos |
Country Status (29)
Country | Link |
---|---|
US (5) | US7947646B2 (es) |
EP (2) | EP2132314B1 (es) |
JP (1) | JP5496682B2 (es) |
KR (5) | KR20090127146A (es) |
CN (2) | CN101679980B8 (es) |
AR (1) | AR065611A1 (es) |
AU (1) | AU2008223338C9 (es) |
BR (1) | BRPI0808332A2 (es) |
CA (1) | CA2679841C (es) |
CL (2) | CL2008000664A1 (es) |
CR (2) | CR11054A (es) |
CY (1) | CY1118857T1 (es) |
DK (1) | DK2132314T3 (es) |
EA (2) | EA201490822A1 (es) |
ES (1) | ES2613043T3 (es) |
HR (1) | HRP20170323T1 (es) |
HU (1) | HUE032260T2 (es) |
IL (2) | IL200605A (es) |
LT (1) | LT2132314T (es) |
MX (2) | MX348286B (es) |
NZ (1) | NZ579369A (es) |
PE (3) | PE20130615A1 (es) |
PH (1) | PH12013502308A1 (es) |
PL (1) | PL2132314T3 (es) |
PT (1) | PT2132314T (es) |
RS (1) | RS55726B1 (es) |
SI (1) | SI2132314T1 (es) |
TW (3) | TWI573802B (es) |
WO (1) | WO2008109167A2 (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2332977B1 (en) | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
CA2624976A1 (en) | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
JP5058261B2 (ja) | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
EP2446896A1 (en) | 2006-12-18 | 2012-05-02 | Acceleron Pharma, Inc. | Activin-ActRII Antagonists for use in Increasing Red Blood Cells, increasing reticulocyte levels, or promoting erythropoiesis |
RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EA025371B1 (ru) | 2007-02-09 | 2016-12-30 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
LT3494986T (lt) | 2008-08-14 | 2020-07-10 | Acceleron Pharma Inc. | Gdf gaudyklės |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
CN104371024A (zh) | 2008-11-26 | 2015-02-25 | 安姆根有限公司 | 激活素iib受体多肽的变异体及其用途 |
AU2013216639B2 (en) * | 2008-11-26 | 2016-05-05 | Amgen Inc. | Variants of activin IIB receptor polypeptides and uses thereof |
AU2016210719B2 (en) * | 2008-11-26 | 2018-03-29 | Amgen Inc. | Variants of activin IIB receptor polypeptides and uses thereof |
WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
MA33279B1 (fr) | 2009-04-27 | 2012-05-02 | Novartis Ag | Compositions et procédés pour l'augmentation de la croissance des muscles |
US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
KR20190090049A (ko) * | 2009-06-12 | 2019-07-31 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
JP5836961B2 (ja) * | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ, インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
ES2658292T3 (es) * | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
CN105440134A (zh) | 2010-08-16 | 2016-03-30 | 安姆根公司 | 结合肌肉生长抑制素的抗体、组合物和方法 |
US20120121576A1 (en) | 2010-11-08 | 2012-05-17 | Jasbir Seehra | Actriia binding agents and uses thereof |
CN107028789A (zh) | 2010-11-12 | 2017-08-11 | 高露洁—棕榄公司 | 口腔护理产品及其使用和制备方法 |
US9365651B2 (en) * | 2011-07-01 | 2016-06-14 | Novartis Ag | Method for treating metabolic disorders by administration of an anti-ActRIIB antibody |
US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
DK2780368T3 (en) | 2011-11-14 | 2018-02-05 | Regeneron Pharma | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
MX358358B (es) * | 2011-12-19 | 2018-08-15 | Amgen Inc | Polipeptidos de receptores de activina variantes y sus usos. |
ES2779698T3 (es) | 2012-03-19 | 2020-08-18 | Brigham & Womens Hospital Inc | Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad |
SG11201408228QA (en) | 2012-06-11 | 2015-01-29 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
NZ747350A (en) | 2012-10-24 | 2020-07-31 | Celgene Corp | Methods for treating anemia |
CA2890217C (en) | 2012-11-02 | 2021-07-20 | Yifu FANG | Activin-actrii antagonists and uses for treating bone and other disorders |
MX2015009901A (es) | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administración de un compuesto de antiactivina a a un sujeto. |
SG11201507413XA (en) * | 2013-03-15 | 2015-10-29 | Amgen Inc | Myostatin antagonism in human subjects |
JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
US10017566B2 (en) | 2013-11-12 | 2018-07-10 | The Brigham And Women's Hospital, Inc. | Growth differentiation factor (GDF) for treatment of diastolic heart failure |
AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
EA201692568A1 (ru) * | 2014-06-13 | 2017-05-31 | Санта Мария Биотерапевтикс, Инк. | Составы с полипептидами-рецепторами и связанные с ними способы |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
TW201627007A (zh) * | 2014-12-08 | 2016-08-01 | 諾華公司 | 用於治療肌力退化症之肌肉生長抑制素(myostatin)或活化素(activin)拮抗劑 |
WO2016128523A1 (en) | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
US9744985B2 (en) | 2015-02-17 | 2017-08-29 | Hyundai Motor Company | Rack bar unit of vehicle steering device |
WO2016164503A1 (en) | 2015-04-06 | 2016-10-13 | Acceleron Pharma Inc. | Alk7:actriib heteromultimers and uses thereof |
JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームi型およびii型受容体融合タンパク質およびその使用 |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
MX2017013267A (es) | 2015-04-15 | 2018-08-15 | Regeneron Pharma | Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8). |
PL3286206T3 (pl) * | 2015-04-22 | 2021-09-13 | Biogen Ma Inc. | Nowe hybrydowe białka pułapki na ligand actriib do leczenia chorób powodujących zanik mięśni |
RU2651776C2 (ru) * | 2015-12-01 | 2018-04-23 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | Биспецифические антитела против cd3*cd19 |
JP6948331B2 (ja) | 2016-01-06 | 2021-10-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する |
AU2017230091B2 (en) | 2016-03-10 | 2022-04-07 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
KR20190075078A (ko) | 2016-10-05 | 2019-06-28 | 악셀레론 파마 인코포레이티드 | ALK4:ActRIIB 이형다량체 및 이의 용도 |
JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
CA3087008A1 (en) | 2018-01-12 | 2019-07-18 | Keros Therapeutics, Inc. | Activin receptor type iib variants and methods of use thereof |
MA52417A (fr) | 2018-03-01 | 2021-01-06 | Regeneron Pharma | Procédés de modification de composition corporelle |
WO2023108137A1 (en) * | 2021-12-10 | 2023-06-15 | Biogen Ma Inc. | Modified actriib proteins and methods of use thereof |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2899886A (en) * | 1959-08-18 | rodth | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
JPS5349966A (en) | 1976-10-18 | 1978-05-06 | Hitachi Ltd | Manufacture of semiconductor integrated circuit |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
US20050186593A1 (en) * | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
US5885794A (en) * | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
DK0521187T3 (da) * | 1991-07-05 | 1996-03-18 | Nestle Sa | Indretning til ekstraktion af patroner der kan tilpasses til alle espressomaskiner |
EP0521510B1 (fr) * | 1991-07-05 | 1996-12-27 | Societe Des Produits Nestle S.A. | Cartouche rigide pour café et son procédé de fabrication |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
AU702163B2 (en) | 1994-04-29 | 1999-02-18 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP4454859B2 (ja) | 1998-11-13 | 2010-04-21 | イミュネックス・コーポレーション | ヒトtslpdnaおよびポリペプチド |
JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
JP2000262405A (ja) * | 1999-03-18 | 2000-09-26 | Soc Prod Nestle Sa | 飲料抽出用密封カートリッジ |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
TWI236360B (en) * | 2000-06-30 | 2005-07-21 | Nestle Sa | Capsule cage |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
PT1190959E (pt) * | 2000-09-26 | 2004-06-30 | Nestle Sa | Pacote fechado para confeccao de uma bebida previsto para ser extraido sob pressao |
EP1203554A1 (fr) * | 2000-11-03 | 2002-05-08 | Societe Des Produits Nestle S.A. | Dispositif pour l'extraction d'une substance alimentaire contenue dans un élément de recharge |
PT1208782E (pt) * | 2000-11-28 | 2004-10-29 | Nestle Sa | Dispositivo de percolacao |
US20050188854A1 (en) * | 2002-02-07 | 2005-09-01 | The Coca-Cola Co. | Coffee and tea dispenser |
US6786134B2 (en) * | 2002-02-07 | 2004-09-07 | The Coca-Cola Company | Coffee and tea dispenser |
GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
FR2842092B1 (fr) * | 2002-07-12 | 2004-12-24 | Seb Sa | Machine a cafe fonctionnant avec des doses |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7511012B2 (en) | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
CA2526669A1 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
US8327754B2 (en) * | 2003-07-22 | 2012-12-11 | The Coca-Cola Company | Coffee and tea pod |
US20060196364A1 (en) * | 2003-07-22 | 2006-09-07 | The Coca-Cola Company | Coffee & Tea Pod |
DK3260117T3 (da) | 2003-09-12 | 2019-07-01 | Amgen Inc | Hurtigt opløsende formulering, der omfatter cinacalcet-hcl |
US7074445B2 (en) * | 2003-10-30 | 2006-07-11 | Frito-Lay North America, Inc. | Method for adhering large seasoning bits to a food substrate |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
GB2411106B (en) * | 2004-02-17 | 2006-11-22 | Kraft Foods R & D Inc | Cartridge for the preparation of beverages |
PL1750683T3 (pl) | 2004-04-23 | 2013-05-31 | Amgen Inc | Formuły o przedłużonym uwalnianiu |
EP2332977B1 (en) | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
GB2416480B (en) * | 2004-07-27 | 2007-12-27 | Kraft Foods R & D Inc | A system for the preparation of beverages |
WO2006020884A2 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
ES2629397T3 (es) | 2004-09-24 | 2017-08-09 | Amgen Inc. | Moléculas de Fc modificadas |
EP1640756A1 (en) * | 2004-09-27 | 2006-03-29 | Barco N.V. | Methods and systems for illuminating |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
JP5161777B2 (ja) | 2005-09-07 | 2013-03-13 | アムジェン フレモント インク. | アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体 |
PL1775234T3 (pl) * | 2005-10-14 | 2009-01-30 | Nestec Sa | Kapsułka do przygotowywania napoju |
US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
US20080014860A1 (en) * | 2006-07-14 | 2008-01-17 | Lynn Byron Heitman | Method and apparatus for eliminating register boxes, improving penetration sealing, improving airflow and reducing the labor costs to install ceiling registers |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
EP2446896A1 (en) | 2006-12-18 | 2012-05-02 | Acceleron Pharma, Inc. | Activin-ActRII Antagonists for use in Increasing Red Blood Cells, increasing reticulocyte levels, or promoting erythropoiesis |
TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
US8318135B2 (en) | 2007-03-19 | 2012-11-27 | National Research Council Of Canada | Antagonist of ligands and uses thereof |
US8431175B2 (en) * | 2007-06-05 | 2013-04-30 | Nestec S.A. | Method for preparing a beverage or food liquid and system using brewing centrifugal force |
JP5082676B2 (ja) * | 2007-08-23 | 2012-11-28 | 株式会社サタケ | 光学式穀物選別機 |
EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
EP3363453A1 (en) | 2008-06-26 | 2018-08-22 | Acceleron Pharma Inc. | Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders |
CA2730156A1 (en) * | 2008-07-08 | 2010-01-14 | Nestec S.A. | Portion-controlled nutrition system and method using capsules |
US8151694B2 (en) * | 2008-08-01 | 2012-04-10 | Keurig, Incorporated | Beverage forming apparatus with centrifugal pump |
LT3494986T (lt) | 2008-08-14 | 2020-07-10 | Acceleron Pharma Inc. | Gdf gaudyklės |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
CA2734935C (en) * | 2008-09-02 | 2015-02-10 | Nestec S.A. | Controlled beverage production device using centrifugal forces |
CN104371024A (zh) | 2008-11-26 | 2015-02-25 | 安姆根有限公司 | 激活素iib受体多肽的变异体及其用途 |
WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
MA33279B1 (fr) | 2009-04-27 | 2012-05-02 | Novartis Ag | Compositions et procédés pour l'augmentation de la croissance des muscles |
US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
WO2011085165A2 (en) | 2010-01-08 | 2011-07-14 | The Brigham And Women's Hospital, Inc. | Ca-125 immune complexes as biomarkers of ovarian cancer |
MX2011011596A (es) | 2010-03-31 | 2012-02-01 | Keryx Biopharmaceuticals Inc | Perifosina y capecitabina como un tratamiento combinado para cancer. |
US20120121576A1 (en) | 2010-11-08 | 2012-05-17 | Jasbir Seehra | Actriia binding agents and uses thereof |
MX358358B (es) | 2011-12-19 | 2018-08-15 | Amgen Inc | Polipeptidos de receptores de activina variantes y sus usos. |
WO2013106715A1 (en) | 2012-01-13 | 2013-07-18 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
JP5782185B2 (ja) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2008
- 2008-03-05 TW TW103117408A patent/TWI573802B/zh not_active IP Right Cessation
- 2008-03-05 US US12/074,877 patent/US7947646B2/en active Active
- 2008-03-05 TW TW105129851A patent/TW201718635A/zh unknown
- 2008-03-05 TW TW097107642A patent/TWI454479B/zh not_active IP Right Cessation
- 2008-03-06 EA EA201490822A patent/EA201490822A1/ru unknown
- 2008-03-06 JP JP2009552758A patent/JP5496682B2/ja active Active
- 2008-03-06 RS RS20170192A patent/RS55726B1/sr unknown
- 2008-03-06 KR KR1020097020320A patent/KR20090127146A/ko not_active Application Discontinuation
- 2008-03-06 WO PCT/US2008/003119 patent/WO2008109167A2/en active Application Filing
- 2008-03-06 CN CN200880007116.0A patent/CN101679980B8/zh not_active Expired - Fee Related
- 2008-03-06 ES ES08742032.9T patent/ES2613043T3/es active Active
- 2008-03-06 EP EP08742032.9A patent/EP2132314B1/en active Active
- 2008-03-06 KR KR1020157003616A patent/KR101633727B1/ko active IP Right Grant
- 2008-03-06 AU AU2008223338A patent/AU2008223338C9/en active Active
- 2008-03-06 SI SI200831764A patent/SI2132314T1/sl unknown
- 2008-03-06 MX MX2015002054A patent/MX348286B/es unknown
- 2008-03-06 PE PE2012002108A patent/PE20130615A1/es not_active Application Discontinuation
- 2008-03-06 PT PT87420329T patent/PT2132314T/pt unknown
- 2008-03-06 CA CA2679841A patent/CA2679841C/en active Active
- 2008-03-06 CL CL200800664A patent/CL2008000664A1/es unknown
- 2008-03-06 HU HUE08742032A patent/HUE032260T2/en unknown
- 2008-03-06 BR BRPI0808332-0A patent/BRPI0808332A2/pt not_active IP Right Cessation
- 2008-03-06 LT LTEP08742032.9T patent/LT2132314T/lt unknown
- 2008-03-06 EA EA200970810A patent/EA020510B1/ru not_active IP Right Cessation
- 2008-03-06 PE PE2017001328A patent/PE20171325A1/es not_active Application Discontinuation
- 2008-03-06 PL PL08742032T patent/PL2132314T3/pl unknown
- 2008-03-06 AR ARP080100918A patent/AR065611A1/es not_active Application Discontinuation
- 2008-03-06 KR KR1020147010346A patent/KR101633728B1/ko active IP Right Grant
- 2008-03-06 DK DK08742032.9T patent/DK2132314T3/en active
- 2008-03-06 CN CN201610218042.1A patent/CN105924516A/zh active Pending
- 2008-03-06 MX MX2009009495A patent/MX2009009495A/es active IP Right Grant
- 2008-03-06 KR KR1020127008467A patent/KR101428344B1/ko not_active IP Right Cessation
- 2008-03-06 KR KR1020167016449A patent/KR20160075861A/ko active IP Right Grant
- 2008-03-06 PE PE2008000436A patent/PE20081804A1/es not_active Application Discontinuation
- 2008-03-06 NZ NZ579369A patent/NZ579369A/en not_active IP Right Cessation
- 2008-03-06 EP EP16194631.4A patent/EP3141605A1/en not_active Withdrawn
-
2009
- 2009-08-27 IL IL200605A patent/IL200605A/en not_active IP Right Cessation
- 2009-10-05 CR CR11054A patent/CR11054A/es not_active Application Discontinuation
-
2011
- 2011-04-05 US US13/080,515 patent/US8716459B2/en active Active
-
2013
- 2013-11-11 PH PH12013502308A patent/PH12013502308A1/en unknown
-
2014
- 2014-03-11 US US14/204,460 patent/US9447165B2/en active Active
-
2015
- 2015-02-24 CR CR20150094A patent/CR20150094A/es unknown
- 2015-10-23 CL CL2015003139A patent/CL2015003139A1/es unknown
-
2016
- 2016-06-02 US US15/171,944 patent/US9809638B2/en active Active
- 2016-10-13 IL IL248322A patent/IL248322A0/en unknown
-
2017
- 2017-02-22 CY CY20171100238T patent/CY1118857T1/el unknown
- 2017-02-27 HR HRP20170323TT patent/HRP20170323T1/hr unknown
- 2017-09-25 US US15/714,726 patent/US10407487B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150094A (es) | Variantes de los polipeptidos del receptor de activina y usos de los mismos | |
CR20160443A (es) | Variantes de polipéptidos receptores de activina iib y aplicaciones de éstos (divisional) | |
CR20140304A (es) | Polipeptidos de receptores de activina variantes y sus usos | |
DK3595668T3 (da) | Benzazepinforbindelser, konjugater og anvendelser deraf | |
EA201100908A1 (ru) | Расширенные растворимые полипептиды рн20 и их использование | |
DK3640208T3 (da) | Molekularsi scm-14, syntesefremgangsmåde dertil og anvendelse deraf | |
CY1118250T1 (el) | Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων | |
MX2017008215A (es) | Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina. | |
BRPI0919390A8 (pt) | quinazolinone, quinolone e análogos relacionados como muduladores sirtuinais. | |
EA200801758A1 (ru) | Лекарственные формы, устойчивые к самовольному изменению | |
HN2008000178A (es) | Compuestos triciclicos, composiciones y procedimientos | |
MX346423B (es) | Conjugados de polimeros zwiterionicos multifuncionales. | |
GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
BRPI0903493A2 (pt) | Retardantes de chama isentos de halogênio | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
ATE530170T1 (de) | Paliperidonformulierung mit verzögerter freisetzung | |
BRPI0819934A2 (pt) | Fibra conjugada, pano não-tecido, e, artigo conformado. | |
BRPI0819429A2 (pt) | Aparelhos de transmissão e de recepção. | |
EA201000258A1 (ru) | Новые гербициды | |
ECSP11011021A (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
TR201901977T4 (tr) | Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri. | |
BRPI0809913A2 (pt) | Derivados de 2,6-naftiridina como moduladores da proteína quinase | |
CL2008000091A1 (es) | Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria. | |
BR112019006558A2 (pt) | compostos inovadores | |
NO20091386L (no) | Fenyloksyanilinderivater |